Dr Marwan Kwok MB ChB, MRCP (UK), PhD, FRCPath

• CCT, Certificate of Completion of Training (Haematology), General Medical Council, 2021
• FRCPath, Fellowship of the Royal College of Pathologists, 2020
• PhD, Doctor of Philosophy, University of Birmingham, 2018
• MRCP (UK), Membership of the Royal College of Physicians, 2013
• MB ChB, Bachelor of Medicine and Bachelor of Surgery, University of Leeds, 2009
• BSc, Bachelor of Science (with first class honours), University College London, 2006

MB ChB  Year 3 – Clinical Core lecture programme 

BSc Biomedical Sciences Year 3 – Cancer Pathogenesis and Treatment module 

MSc Clinical Oncology – Haemato-oncology module (module co-lead) 

Ad hoc clinical teaching of medical students and junior doctors

Dr Kwok has led previous studies to establish the mechanistic basis of ATR pathway inhibition as a therapeutic approach for lymphoid malignancies (Blood; 2016; 127: 582-595) as well as the long-term prognostic impact of minimal residual disease in CLL (Blood; 2016; 128: 2770-2773). He also contributed to major studies on the natural history of monoclonal B cell lymphocytosis (MBL) and on other novel therapeutic targets for high-risk CLL. More recently, he initiated and led a study which provided the first substantive integrative analysis of spontaneous CLL regression, yielding biological insight into this rare but important phenomenon (Blood; 2020; 135: 411-428). 

His current research, funded through Cancer Research UK (£1.1 M; 2022-2027), seeks to extend his recent work on spontaneous CLL regression to address the important question of how tumour biology and immunogenicity, as well as its interaction with the immune microenvironment, underpin differences in the clinical trajectory of cancer patients, such as between patients with spontaneously regressing and progressing disease, and between those with durable and short-lived responses to treatment.   

He is currently based at Dana-Farber Cancer Institute within Professor Catherine J Wu’s laboratory, where he collaborates extensively with the Broad Institute (Getz and Carr labs) as well as other UK, US and international centres, including the German CLL Study Group (GCLLSG).

His current studies include: 

1.         Single-cell characterisation of the evolutionary history and biological mechanisms underpinning spontaneous CLL regression;

2.         Analysis of the impact of clonal dynamics and subclonal genetic drivers on the kinetics of response and resistance to conventional and targeted therapy (collaboration with Dr Eugen Tausch, University of Ulm; and the Broad Institute);

3.         Implementation and evaluation of personalised multivalent neoantigen vaccine for immunoprevention and early therapeutic intervention (collaboration with Dr Inhye Ahn, Dana-Farber Cancer Institute).